このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

EFICAC-TTR試験:トランスサイレチン心臓アミロイドーシスにおける運動と栄養補助食品 (EFICAC-TTR)

2026年9月22日 更新者:Universidad de Burgos

トランスサイレチン心臓アミロイドーシス患者における在宅多成分運動プログラムと栄養補給を組み合わせた効果に関する前向き無作為化多施設共同臨床試験

Transthyretin cardiac amyloidosis (TTR-CA) is a systemic cardiac disease that predominantly affects older adults and is frequently associated with reduced physical capacity, muscle weakness, frailty, and impaired quality of life. Although disease-modifying treatments can slow cardiac disease progression, functional and nutritional impairment remain important unmet clinical needs.

EFICAC-TTR is a prospective, randomized, multicenter study designed to evaluate the effects of a 12-week home-based multicomponent exercise program combined with nutritional supplementation in adults aged 70 years or older with confirmed TTR-CA.

A total of 47 participants were randomized to one of three parallel groups: (1) usual medical care; (2) a home-based multicomponent exercise program plus microcrystalline cellulose control supplementation; or (3) the same exercise program plus creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

The primary functional outcomes are change in 6-minute walk test distance and handgrip strength from baseline to 12 weeks. Secondary outcomes include body composition, frailty, quality of life, and nutritional and clinical variables. Mechanistic biomarkers are assessed as exploratory outcomes.

The study aims to determine whether combining exercise with nutritional supplementation can improve functional capacity and related health outcomes in older adults with TTR-CA.

調査の概要

詳細な説明

Participants were randomized to three parallel study groups. The usual-care group continued standard clinical management without a structured exercise program or study supplementation. Participants in the two exercise groups performed the same 12-week home-based multicomponent exercise program adapted to individual functional capacity.

In addition to exercise, one group received daily microcrystalline cellulose as a control supplement, whereas the experimental group received creatine monohydrate (3 g/day) plus beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day). The supplement comparison was blinded, while the comparison with usual care was necessarily open because of the behavioral intervention. Functional outcomes were assessed at baseline and after 12 weeks.

Biological samples collected at baseline and after the intervention are used for exploratory mechanistic analyses.

研究の種類

介入

入学 (実際)

47

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Castille and León
      • Aranda de Duero、Castille and León、スペイン
        • Hospital Santos Reyes
      • Burgos、Castille and León、スペイン、09006
        • Hospital Universitario de Burgos
      • Soria、Castille and León、スペイン
        • Hospital Santa Bárbara

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

70年歳以上 (高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥70 years.
  • Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA) based on positive bone scintigraphy with diphosphonates (Perugini grade 2 or 3) and absence of monoclonal protein.
  • Clinical stability during the 4 weeks prior to enrollment.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion Criteria:

  • Light-chain (AL) amyloidosis or other non-TTR amyloidosis variants.
  • Absolute medical contraindication to moderate-intensity exercise.
  • Severe comorbid conditions with an estimated life expectancy <6 months.
  • Severe cognitive impairment (Mini-Mental State Examination score <20).
  • Concurrent participation in another clinical trial or structured exercise program.
  • Known allergy or intolerance to creatine, beta-hydroxy-beta-methylbutyrate (HMB), or microcrystalline cellulose.
  • Severe renal impairment requiring dialysis.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
他の:Usual Care

Participants received usual medical care for transthyretin cardiac amyloidosis, including routine cardiology follow-up and general lifestyle and nutritional recommendations, without the structured study exercise program or study supplementation.

Standard clinical management for transthyretin cardiac amyloidosis according to routine cardiology practice.

プラセボコンパレーター:Exercise + Microcrystalline Cellulose Control Supplementation

Participants performed a 12-week home-based multicomponent exercise program and received daily microcrystalline cellulose as the control supplement. The supplement was provided in sachets matched to the supplementation procedure used in the experimental arm.

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with microcrystalline cellulose, used as a nutritionally inert control supplement to match supplementation procedures.

実験的:Exercise + Creatine and HMB Supplementation

Participants performed the same 12-week home-based multicomponent exercise program and received daily supplementation with creatine monohydrate (3 g/day) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g/day).

A 12-week home-based multicomponent exercise program adapted from the Vivifrail model, including strength, balance, mobility, and endurance exercises tailored to individual functional capacity.

Daily oral supplementation with creatine monohydrate (3 g/day) and β-hydroxy-β-methylbutyrate (HMB, 3 g/day) for 12 weeks.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Handgrip Strength
時間枠:Baseline and 12 weeks

Change in maximal isometric handgrip strength measured in kilograms (kg) using a calibrated handheld dynamometer (best of three attempts for the dominant hand), expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in 6-Minute Walk Test Distance
時間枠:Baseline and 12 weeks

Change in walking capacity assessed by the 6-minute walk test, measured as the difference in total distance walked (meters) between baseline and 12 weeks.

Baseline and 12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Fat Mass
時間枠:Baseline and 12 weeks

Change in total body fat mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Skeletal Muscle Mass
時間枠:Baseline and 12 weeks

Change in skeletal muscle mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Fat-Free Mass
時間枠:Baseline and 12 weeks

Change in fat-free mass measured in kilograms (kg) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Phase Angle
時間枠:Baseline and 12 weeks

Change in phase angle measured in degrees (°) using multifrequency bioelectrical impedance analysis, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Frailty Status Assessed by the FRAIL Scale
時間枠:Baseline and 12 weeks

Change in frailty status assessed by the FRAIL scale, a 5-item questionnaire with scores ranging from 0 to 5, where higher scores indicate greater frailty, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Short Physical Performance Battery (SPPB) Score
時間枠:Baseline and 12 weeks

Change in Short Physical Performance Battery (SPPB) total score, ranging from 0 to 12 points, where higher scores indicate better physical performance, expressed as the difference between baseline and 12 weeks.

Baseline and 12 weeks
Change in Clinical Frailty Scale (CFS) Score
時間枠:Baseline and 12 weeks

Change in frailty severity assessed by the Clinical Frailty Scale (CFS), a 9-point ordinal scale ranging from 1 (very fit) to 9 (terminally ill), where higher scores indicate greater frailty.

Baseline and 12 weeks
Change in Barthel Index Score
時間枠:Baseline and 12 weeks

Change in functional independence assessed by the Barthel Index, scored from 0 to 100, where higher scores indicate greater independence.

Baseline and 12 weeks
Change in SARC-F Score
時間枠:Baseline and 12 weeks

Change in sarcopenia risk assessed by the SARC-F questionnaire, with scores ranging from 0 to 10, where higher scores indicate greater sarcopenia risk.

Baseline and 12 weeks
Change in Minnesota Living With Heart Failure Questionnaire Score
時間枠:Baseline and 12 weeks

Change in health-related quality of life assessed by the Minnesota Living With Heart Failure Questionnaire (MLHFQ), with total scores ranging from 0 to 105, where higher scores indicate worse quality of life.

Baseline and 12 weeks
Change in Charlson Comorbidity Index
時間枠:Baseline and 12 weeks

Change in comorbidity burden assessed using the Charlson Comorbidity Index, a weighted index that accounts for the number and severity of comorbid conditions, where higher scores indicate greater comorbidity burden.

Baseline and 12 weeks
Exercise Program Adherence
時間枠:Up to 12 weeks

Proportion (%) of prescribed exercise sessions completed, with adequate adherence defined as completion of at least 80% of prescribed sessions.

Up to 12 weeks
Supplement Adherence
時間枠:Up to 12 weeks

Proportion (%) of planned supplement doses consumed, with optimal compliance defined as 90-110%.

Up to 12 weeks
Change in Mini Nutritional Assessment Short-Form (MNA-SF) Score
時間枠:Baseline and 12 weeks

Change in nutritional status assessed by the Mini Nutritional Assessment Short-Form (MNA-SF), with scores ranging from 0 to 14 points, where lower scores indicate poorer nutritional status and greater risk of malnutrition.

Baseline and 12 weeks
Incidence of Intervention-Related Adverse Events
時間枠:Up to 12 weeks

Number and type of adverse events related to exercise and/or supplementation, classified according to severity and relatedness, collected during the 12-week intervention period.

Up to 12 weeks
Rate of Supplement Discontinuation
時間枠:Up to 12 weeks

Proportion of participants who discontinue study supplementation during the intervention period.

Up to 12 weeks
Change in Skeletal Muscle Index (SMI)
時間枠:Baseline and 12 weeks

Change in skeletal muscle index (SMI), expressed as skeletal muscle mass normalized to height squared (kg/m²), measured using multifrequency bioelectrical impedance analysis, between baseline and 12 weeks.

Baseline and 12 weeks

その他の成果指標

結果測定
メジャーの説明
時間枠
Change in Growth Differentiation Factor 15 (GDF-15)
時間枠:Baseline and 12 weeks

Change in serum GDF-15 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Soluble ST2
時間枠:Baseline and 12 weeks

Change in serum soluble ST2 concentration (ng/mL) measured by immunoassay.

Baseline and 12 weeks
Change in Interleukin-6 (IL-6)
時間枠:Baseline and 12 weeks

Change in serum interleukin-6 (IL-6) concentration (pg/mL) measured by immunoassay.

Baseline and 12 weeks
Change in C-Reactive Protein (CRP)
時間枠:Baseline and 12 weeks

Change in serum C-reactive protein (CRP) concentration (mg/dL) measured by immunoassay.

Baseline and 12 weeks
Change in circulating miR-21 expression
時間枠:Baseline and 12 weeks

Change in circulating miR-21 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-29 expression
時間枠:Baseline and 12 weeks

Change in circulating miR-29 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-34a expression
時間枠:Baseline and 12 weeks

Change in circulating miR-34a expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in circulating miR-155 expression
時間枠:Baseline and 12 weeks

Change in circulating miR-155 expression measured by quantitative PCR, expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in PBMC Immune Polarization Profile by Flow Cytometry
時間枠:Baseline and 12 weeks

Change in the immunophenotypic profile of peripheral blood mononuclear cells (PBMCs) assessed by multiparametric flow cytometry, including the relative abundance of cell populations with M1-like and M2-like phenotypes and their ratio.

Baseline and 12 weeks
Change in Pro-inflammatory (M1) Gene Expression Markers
時間枠:Baseline and 12 weeks

Change in gene expression of predefined pro-inflammatory (M1-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Anti-inflammatory (M2) Gene Expression Markers
時間枠:Baseline and 12 weeks

Change in gene expression of predefined anti-inflammatory/regenerative (M2-associated) markers in peripheral blood mononuclear cells (PBMCs), measured by quantitative PCR and expressed as relative expression (ΔΔCt).

Baseline and 12 weeks
Change in Serum Albumin
時間枠:Baseline and 12 weeks

Change in serum albumin concentration (g/dL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Serum Prealbumin
時間枠:Baseline and 12 weeks

Change in serum prealbumin concentration (g/dL) between baseline and 12 weeks

Baseline and 12 weeks
Change in Vitamin D
時間枠:Baseline and 12 weeks

Change in serum 25-hydroxyvitamin D concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Galectin-3
時間枠:Baseline and 12 weeks

Change in serum galectin-3 concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in NT-proBNP
時間枠:Baseline and 12 weeks

Change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in High-Sensitivity Troponin T
時間枠:Baseline and 12 weeks

Change in serum high-sensitivity cardiac troponin T concentration (ng/L) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Leptin
時間枠:Baseline and 12 weeks

Change in serum leptin concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Adiponectin
時間枠:Baseline and 12 weeks

Change in serum adiponectin concentration (µg/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in IGF-1
時間枠:Baseline and 12 weeks

Change in serum insulin-like growth factor 1 (IGF-1) concentration (ng/mL) between baseline and 12 weeks.

Baseline and 12 weeks
Change in Klotho
時間枠:Baseline and 12 weeks

Change in serum Klotho concentration (pg/mL) between baseline and 12 weeks.

Baseline and 12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Juan Mielgo-Ayuso, PhD、Universidad de Burgos
  • 主任研究者:José A Pérez Rivera, PhD, MD、Hospital Universitario de Burgos

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年2月3日

一次修了 (実際)

2026年9月10日

研究の完了 (実際)

2026年9月10日

試験登録日

最初に提出

2025年12月17日

QC基準を満たした最初の提出物

2026年1月7日

最初の投稿 (実際)

2026年1月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data that underlie the results reported in publications will be made available upon reasonable request.

IPD 共有時間枠

Beginning 6 months after publication and ending 5 years after publication.

IPD 共有アクセス基準

Access to de-identified individual participant data will be granted upon reasonable request to the principal investigator. Requests must include a methodologically sound research proposal and will be evaluated for scientific merit and feasibility. Data sharing will require the execution of a data sharing agreement and will comply with applicable data protection and privacy regulations.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する